1syv: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:1syv.png|left|200px]] | [[Image:1syv.png|left|200px]] | ||
{{STRUCTURE_1syv| PDB=1syv | SCENE= }} | {{STRUCTURE_1syv| PDB=1syv | SCENE= }} | ||
===HLA-B*4405 complexed to the dominant self ligand EEFGRAYGF=== | ===HLA-B*4405 complexed to the dominant self ligand EEFGRAYGF=== | ||
{{ABSTRACT_PUBMED_15226359}} | {{ABSTRACT_PUBMED_15226359}} | ||
== | ==About this Structure== | ||
[[1syv]] is a 3 chain structure of [[Beta-2 microglobulin]] and [[Major histocompatibility complex]] with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1SYV OCA]. | |||
== | ==See Also== | ||
*[[Beta-2 microglobulin|Beta-2 microglobulin]] | |||
*[[Major histocompatibility complex|Major histocompatibility complex]] | |||
==Reference== | ==Reference== | ||
<ref group="xtra">PMID: | <ref group="xtra">PMID:015226359</ref><references group="xtra"/> | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Beddoe, T.]] | [[Category: Beddoe, T.]] | ||
| Line 47: | Line 36: | ||
[[Category: Class i]] | [[Category: Class i]] | ||
[[Category: Hla]] | [[Category: Hla]] | ||
[[Category: Immune system]] | |||
[[Category: Mhc]] | [[Category: Mhc]] | ||
Revision as of 15:51, 27 July 2012
HLA-B*4405 complexed to the dominant self ligand EEFGRAYGF
Template:ABSTRACT PUBMED 15226359
About this Structure
1syv is a 3 chain structure of Beta-2 microglobulin and Major histocompatibility complex with sequence from Homo sapiens. Full crystallographic information is available from OCA.
See Also
Reference
- Zernich D, Purcell AW, Macdonald WA, Kjer-Nielsen L, Ely LK, Laham N, Crockford T, Mifsud NA, Bharadwaj M, Chang L, Tait BD, Holdsworth R, Brooks AG, Bottomley SP, Beddoe T, Peh CA, Rossjohn J, McCluskey J. Natural HLA class I polymorphism controls the pathway of antigen presentation and susceptibility to viral evasion. J Exp Med. 2004 Jul 5;200(1):13-24. Epub 2004 Jun 28. PMID:15226359 doi:https://dx.doi.org/10.1084/jem.20031680